Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
34,971,157
-
Shares change
-
+6,433,896
-
Total reported value, excl. options
-
$386,778,183
-
Value change
-
+$65,262,601
-
Put/Call ratio
-
214%
-
Number of buys
-
62
-
Number of sells
-
-74
-
Price
-
$11.06
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2023
175 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q2 2023.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,971,157 shares
.
Largest 10 shareholders include VANGUARD GROUP INC (4,693,817 shares), BlackRock Inc. (4,396,970 shares), STATE STREET CORP (4,180,224 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2,077,893 shares), UBS Group AG (1,359,471 shares), Caligan Partners LP (1,293,510 shares), CITIGROUP INC (1,161,401 shares), PICTET ASSET MANAGEMENT SA (955,005 shares), BOOTHBAY FUND MANAGEMENT, LLC (941,755 shares), and DG Capital Management, LLC (896,294 shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.